165 related articles for article (PubMed ID: 22133386)
1. Tipranavir in the protease inhibitors arena.
Vergani B; Rusconi S
Drugs R D; 2011 Dec; 11(4):291-3. PubMed ID: 22133386
[No Abstract] [Full Text] [Related]
2. [Perspectives: hope for therapy experienced patients. Tipranavir shows superior effectiveness with comparable safety].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():44-5. PubMed ID: 16385873
[No Abstract] [Full Text] [Related]
3. Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes.
Stürmer M; Stephan C; Gute P; Knecht G; Bickel M; Brodt HR; Doerr HW; Gürtler L; Lecocq P; van Houtte M
Antimicrob Agents Chemother; 2011 Nov; 55(11):5362-6. PubMed ID: 21825300
[TBL] [Abstract][Full Text] [Related]
4. Tipranavir (Aptivus) for HIV.
Med Lett Drugs Ther; 2005 Oct; 47(1219):83-4. PubMed ID: 16247341
[TBL] [Abstract][Full Text] [Related]
5. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.
Raffi F; Battegay M; Rusconi S; Opravil M; Blick G; Steigbigel RT; Kraft M; Neubacher D; Sabo JP
AIDS; 2007 Sep; 21(14):1977-80. PubMed ID: 17721109
[TBL] [Abstract][Full Text] [Related]
6. A lame duck, a dark horse, and a goat.
Huff B
GMHC Treat Issues; 2005; 19(5-6):4-5. PubMed ID: 16193576
[No Abstract] [Full Text] [Related]
7. Tipranavir: a protease inhibitor for multi-drug resistant HIV-1.
Best B; Haubrich R
Expert Opin Investig Drugs; 2006 Jan; 15(1):59-70. PubMed ID: 16370934
[TBL] [Abstract][Full Text] [Related]
8. Reviving protease inhibitors: new data and more options.
Murphy RL
J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S43-52; quiz S53, S55-6. PubMed ID: 12946064
[No Abstract] [Full Text] [Related]
9. Some existing drugs work on resistant HIV.
AIDS Alert; 2000 Jan; 15(1):10-2. PubMed ID: 11366357
[TBL] [Abstract][Full Text] [Related]
10. Trial of tipranavir versus darunavir in treatment-experienced patients enrolling.
AIDS Patient Care STDS; 2007 Aug; 21(8):6-3. PubMed ID: 17902242
[No Abstract] [Full Text] [Related]
11. The RESIST trials--superiority of tipranavir over other PIs.
Gonzalez-Lahoz J
AIDS Rev; 2004; 6(4):244-5. PubMed ID: 15793936
[No Abstract] [Full Text] [Related]
12. Protease inhibitors: the current status.
Dauer B
J HIV Ther; 2005 Dec; 10(4):72-4. PubMed ID: 16519246
[No Abstract] [Full Text] [Related]
13. Anti-HIV agents. Tipranavir for treatment-experienced PHAs.
TreatmentUpdate; 2007 Jan; 19(1):8. PubMed ID: 17390481
[No Abstract] [Full Text] [Related]
14. [Desensitization to tipranavir caused by toxicodermia].
Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E
Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397
[No Abstract] [Full Text] [Related]
15. Salvage therapy update.
Emery C
Surviv News (Atlanta Ga); 2005; 16(6):8. PubMed ID: 16388538
[No Abstract] [Full Text] [Related]
16. FDA approves tipranavir.
IAPAC Mon; 2005 Jul; 11(7):190. PubMed ID: 16676422
[No Abstract] [Full Text] [Related]
17. Tipranavir.
Gallant J
Drugs; 2003; 63(15):1619-20. PubMed ID: 12887269
[No Abstract] [Full Text] [Related]
18. New hope in tipranavir. New Boehringer-Ingelheim protease inhibitor may succeed where others fall short.
Rodriguez E
Posit Living; 2001; 10(6):15. PubMed ID: 11702749
[No Abstract] [Full Text] [Related]
19. Tipranavir reduces viral load.
AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412583
[No Abstract] [Full Text] [Related]
20. Tipranavir gets approved.
AIDS Patient Care STDS; 2005 Sep; 19(9):615-6. PubMed ID: 16245408
[No Abstract] [Full Text] [Related]
[Next] [New Search]
